CN Patent

CN111138437B — 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途

Assigned to Hangzhou Huadong Medicine Group Biopharmaceutical Co ltd · Expires 2021-03-05 · 5y expired

What this patent protects

本发明公开了一种取代的吡唑并[1,5‑a]嘧啶氨基酸衍生物及其用途。该系列化合物保留了吡唑并[1,5‑a]嘧啶基团，并且引入具有亲水性基团羧基的人体必需氨基酸。本发明化合物不仅具有较强的Trk激酶抑制效果，而且具有安全性高、水溶性好等特点。

USPTO Abstract

本发明公开了一种取代的吡唑并[1,5‑a]嘧啶氨基酸衍生物及其用途。该系列化合物保留了吡唑并[1,5‑a]嘧啶基团，并且引入具有亲水性基团羧基的人体必需氨基酸。本发明化合物不仅具有较强的Trk激酶抑制效果，而且具有安全性高、水溶性好等特点。

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CN111138437B
Jurisdiction: CN
Classification: —
Expires: 2021-03-05
Drug substance claim: No
Drug product claim: No
Assignee: Hangzhou Huadong Medicine Group Biopharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.